Summary
The aetiology of clozapine-induced agranulocytosis remains unknown. Leading candidates include an immune mechanism that is possibly complement- or drug-dependent and a toxic mechanism. We analysed these mechanisms by culturing the granulocyte precursor stem cell from the bone marrow in the presence of patients’ serum, clozapine or clozapine metabolites. Studies with patients’ serum failed to identify an immune mechanism. On the basis of our preliminary data, it appears that a toxic mechanism may be responsible, and this is more likely to be due to a metabolite than to clozapine itself Further studies are required to determine the sensitivity of bone marrow precursors to these clozapine derivatives. For instance, prospective collection of serum will make it possible to evaluate whether high metabolite concentrations develop in sensitive individuals and whether they are responsible for agranulocytosis. If such elevated levels occur, further studies will be required to determine whether prospective monitoring will effectively identify patients at risk and ultimately prevent the onset of agranulocytosis by early discontinuation of the drug.
Similar content being viewed by others
References
Ackenheil M. Clozapine-pharmacokinetic investigations and biochemical effects in man. Psychopharmacology 99: S32–S37, 1989
Anderman B, Griffith RW. Clozapine-induced agranulocytosis: a situation report up to August 1976. European Journal of Clinical Pharmacology 11: 199–201, 1977
Bagby Jr GC, Lawrence HJ, Neerhout RC. T-lymphocyte-me-diated granulocyte failure. New England Journal of Medicine 309: 1073–1078, 1983
Baldessarini RJ, Frankenburg FR. Clozapine: a novel antipsychotic agent. New England Jounal of Medicine 324: 746–754, 1991
Barnhart ER. Physicians Desk Reference. 45th Ed., p. 1838, Medical Economics Co. Ltd., Oradell, NJ, 1991
Bondesson U, Lindström LH. Determination of clozapine and its N-demethylated metabolite in plasma by use of gas chromatography-mass spectrometry with single ion detection. Psycho-pharmacology 95: 472–475, 1988
Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. Lancet 336: 785–787, 1990
Ereshefsky L, Watanabe MD, Tran-Johnson TK. Clozapine: an atypical antipsychotic agent. Clinical Pharmacy 8: 691–709, 1989
Gallicchio VS, Hulette BC. In vitro effect of lithium on carbamazepine-induced inhibition of murine and human bone marrow-derived granulocyte-macrophage, erythroid, and megakaryocyte progenitor stem cells. Proceedings of the Society for Experimental Biology and Medicine 190: 109–116, 1989
Gerson SL, Lieberman JA, Friedenberg WR, Lee D, Marx Jr JJ, et al. Polypharmacy in fatal clozapine-associated agranulocytosis. Lancet 338: 262, 1991
Gualde N, Malinvaud G. In vitro generation of cytotoxic lymphocytes during noramidopyrine-induced agranulocytosis. Clinical Immunology and Immunopathology 24: 220–226, 1982
Haring C, Bamas C, Humpel C, Sana A, Fleischhacker WW. Dose-related plasma levels of clozapine. Journal of Clinical Psychopharmacology 9: 71–72, 1989
Idànpààn-Heikkilà J, Alhava E, Olkinuora M, Palva IP. Agranulocytosis during treatment with clozapine. European Journal of Clinical Pharmacology 11: 193–198, 1977
Jefferson JW. Aplastic anemia associated with lithium. Lancet 1: 413, 1975
Jiminez JJ, Arimura GK, Abou-Khalil WH, Isildar M, Yunis AA. Chloramphenicol-induced bone marrow injury: possible role of bacterial metabolites of chloramphenicol. Blood 70: 1180–1185, 1987
Kelton JG, Huang AT, Mold N, Logue G, Rosse WF. The use of in vitro techniques to study drug-induced pancytopenia. New England Journal of Medicine 301: 621–624, 1979
Kramlinger KG, Post RM. Addition of lithium carbonate to carbamazepine: hematological and thyroid effects. American Journal of Psychiatry 147: 615–620, 1990
Krupp P, Barnes P. Leponex-associated granulocytopenia: a review of the situation. Psychopharmacology 99: S118–S121, 1989
Lazarus HM, Andersen J, Chen MG, Variakojis D, Mansour EG, et al. Recombinant granulocyte-macrophage colony stimulating factor after autologous bone marrow transplantation for relapsed non-Hodgkin’s lymphoma: blood and bone marrow progenitor growth studies. A phase II Eastern Cooperative Oncology Group Trial. Blood 78: 830–837, 1991
Lieberman JA, Kane JM, Johns CA. Clozapine: guidelines for clinical management. Journal of Clinical Psychiatry 50: 9–13, 1989a
Lieberman JA, Yunis J, Egea E, Canoso RT, Kane JM, et al. HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia. Archives of General Psychiatry 47: 945–948, 1989b
Mamus SW, Buron JK, Groat JD, Schulte DA, Lobell M, et al. Ibuprofen-associated pure white-cell aplasia. New England Journal of Medicine 314: 623–625, 1986
Murphy JF, Riordan T, Minchinton RM, Chapman JF, Amess JAL, et al. Demonstration of an immune-mediated mechanism of penicillin-induced neutropenia and thrombocytopenia. British Journal of Haematology 55: 155–160, 1983
Neftel KA, Muller MR, Walti M, Erni J, Gugler M, et al. Penicillin G degradation products inhibit in vitro granulopoiesis. British Journal of Haematology 54: 255–260, 1983
Perry PJ, Miller DD, Arndt SV, Cadoret RJ. Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. American Journal of Psychiatry 148: 231–235, 1991
Pisciotta AV. Studies on agranulocytosis: a biochemical defect in chlorpromazine sensitive marrow cells. Journal of Laboratory and Clinical Medicine 78: 435–443, 1971
Pisciotta AV. Immune and toxic mechanisms in drug-induced agranulocytosis. Seminars in Hematology 10: 279–310, 1973
Pisciotta AV, Cronkite C. Aprindine-induced agranulocytosis. Evidence for immunology mechanism. Archives of Internal Medicine 143: 241–243, 1983
Pisciotta AV, Miller RC, Ban S, Cronkite C. Inhibition of fibroblast proliferation by myelotoxic drugs. Annals of the New York Academy of Sciences 459: 198–210, 1985
Simpson GM, Cooper TA. Clozapine plasma levels and convulsions. American Journal of Psychiatry 135: 99–100, 1978
Smith CS, Chinn S, Watts RWE. The sensitivity of human bone marrow granulocyte/monocyte precursor cells to phenylbutazone, oxyphenbutazone and gamma-hydroxyphenylbutazone in vitro, with observations on the bone marrow colony formation in phenylbutazone-induced granulocytopenia. Biochemical Pharmacology 26: 847–852, 1977
Yunis AA. Comparative toxicity of chloramphenicol and thiamphenicol with particular reference to aplastic anemia. Chemioterapie and Antimicrobials 4: 52–61, 1980
Author information
Authors and Affiliations
Additional information
Clozaril®/Leponex®
Rights and permissions
About this article
Cite this article
Gerson, S.L., Meltzer, H. Mechanisms of Clozapine-Induced Agranulocytosis. Drug-Safety 7 (Suppl 1), 17–25 (1992). https://doi.org/10.2165/00002018-199200071-00007
Published:
Issue Date:
DOI: https://doi.org/10.2165/00002018-199200071-00007